Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:10 PM
Ignite Modification Date:
2025-12-24 @ 5:10 PM
NCT ID:
NCT07218250
Eligibility Criteria:
Inclusion Criteria:
* Patient must have pathologically confirmed breast cancer (per EMR).
* Patient with localized or advanced cancer (per EMR).
* Patient is on a waitlist of at least 2 weeks or more for MSK Counseling Center intake and will not complete a Counseling Center intake prior to intervention (these patients will be replaced) (per EMR, patient's care team, or self-report).
* Has no current active or passive suicidal ideation (per self-report of PHQ-9, Item 9: Thoughts that you would be better off dead, or of hurting yourself).
* Female (per EMR)
* Age ≥ 18 (per EMR)
* English fluency - Per self-report: How well do you speak English?
* Agrees to be audio-recorded (per self-report) NOTE: Participants who report Very well are considered fluent.
* Lives in New York, New Jersey, or Connecticut (per self-report).
* Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or informed consent (i.e., acute psychiatric symptoms which require urgent or extended individual treatment) (per EMR, patient's care team, or study team).
* Has no presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, or per self-report of BOMC cognitive test).
* Has no current active or passive suicidal ideation (per item 9 of the PHQ-9 and the CSSRS).
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT07218250
Study Brief:
Protocol Section:
NCT07218250